Strategic design and clinical evaluation of a fixed-dose combination tablet comprising valsartan, amlodipine, rosuvastatin and ezetimibe for patients with hypertension and dyslipidemia

被引:0
作者
Tae-Kwang Kim
Jeong-Eun Lee
Kyuho Jeong
Min-Jun Baek
Dahan Kim
Jun-Young Jeon
Sangyoung Lee
Dae-Duk Kim
机构
[1] Seoul National University,College of Pharmacy
[2] ILDONG Pharmaceutical Co.,Research Institute of Pharmaceutical Sciences and Natural Products Research Institute
[3] Ltd,undefined
[4] Seoul National University,undefined
来源
Journal of Pharmaceutical Investigation | 2024年 / 54卷
关键词
Fixed-dose combination; Valsartan; Amlodipine; Rosuvastatin; Ezetimibe;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:99 / 112
页数:13
相关论文
共 291 条
[1]  
Abdoh A(2004)Amlodipine besylate–excipients interaction in solid dosage form Pharm Dev TecHnol 9 15-24
[2]  
Al-Omari M(2012)Equivalence of two generic brands of amlodipine besylate under biowaiver conditions Int J Pharm Pharm Sci 4 265-268
[3]  
Badwan A(2016)Solubility of rosuvastatin calcium in different neat solvents at different temperatures J Chem Thermodyn 94 230-233
[4]  
Jaber A(2021)A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing Adv Drug Deliv Rev 178 113840-680
[5]  
Akinleye MO(2007)Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study) Am J Cardiol 99 673-427
[6]  
Oyetunde OO(2012)Ezetimibe therapy: mechanism of action and clinical update Vasc Health Risk Manag 8 415-583
[7]  
Okpara HE(2021)Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol Front Cardiovasc Med 8 789931-524
[8]  
Ayerota E(2011)Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy J Med Econ 14 576-580
[9]  
Alshora DH(2005)Drug-drug interaction studies on first-line anti-tuberculosis drugs Pharm Dev Technol 10 517-805
[10]  
Haq N(2021)Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia Expert Rev Cardiovasc Ther 19 575-49